Severe allergic reactions and herpes zoster associated with the use of Picato gel for actinic keratosis
The FDA ( U.S. Food and Drug Administration ) has warned about reports of severe allergic reactions and herpes zoster associated with the use of Picato gel ( Ingenol mebutate ).
Picato is used to treat actinic keratosis, a scaly, crusty lesion on the skin that may be red or yellow in color.
FDA has also received reports of cases involving severe eye injuries and skin reactions associated with the application of Picato gel. Some cases were associated with Picato gel not being used according to the instructions for use on the label.
As a result, FDA has required changes to the label to warn about these new safety risks and to provide additional instructions on the safe and appropriate application of the product.
Patients should use Picato gel as prescribed by their health care professionals, and should not use it on an area of skin larger or for a longer period than instructed in the drug label.
Also patients should avoid applying the gel in, near, and around the mouth, lips and eye area.
Accidental transfer of Picato gel from the hands even after washing has occurred, including through application of make-up and insertion of contact lenses.
Applying Picato gel in a manner other than recommended in the product label has been associated with severe skin reactions and eye injuries.
Patients who experience a severe allergic reaction should stop using Picato gel and seek immediate medical attention.
The allergic reaction may include throat tightness, difficulty breathing, feeling faint, or swelling of the lips or tongue.
Patients should also stop using the product and contact their health care professionals if they develop hives, itching, or severe skin rash.
If accidental eye exposure occurs, flush the eyes thoroughly with water and seek medical care.
Actinic keratosis, which is treated with Picato gel, is a scaly, crusty lesion on the skin that may be red or yellow in color. The lesions are typically located on areas exposed to the sun such as the face, scalp, back of the hands, and chest. The majority of these lesions are not harmful. However, actinic keratosis may occasionally develop into skin cancer. ( Xagena )
Source: FDA, 2015
Jyseleca for the treatment of adults with moderate to severe active rheumatoid arthritis - European Commission approved
The European Commission ( EC ) has granted marketing authorization for Jyseleca ( Filgotinib 200 mg and 100 mg tablets...
SELECT-CHOICE trial: Upadacitinib more effective than Abatacept in patients with moderate to severe active rheumatoid arthritis and prior inadequate response or intolerance to bDMARD
New phase 3 data from the SELECT-CHOICE clinical trial have shown that Upadacitinib ( Rinvoq ), 15 mg, once daily,...
Upadacitinib, a JAK1-selective inhibitor, for adults with moderately to severely active rheumatoid arthritis who fail to adequately respond or are intolerant to Methotrexate
Upadacitinib ( Rinvoq ) was developed as a JAK1-selective inhibitor by exploiting differences in the non-conserved domains outside the active...
Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2...
A meta-analysis of phase III, randomised, placebo-controlled trials has assessed the benefits and harms of Pregabalin ( Lyrica ) in...
FDA has approved Keytruda for adult and pediatric patients with classical Hodgkin lymphoma refractory to treatment, or who have relapsed after three or more prior lines of therapy
The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death...
European Commission has approved Empliciti for the treatment of multiple myeloma in adult patients who have received at least one prior therapy
The European Commission has approved Empliciti ( Elotuzumab ) for the treatment of multiple myeloma as combination therapy with Revlimid...
Heavily pre-treated patients with relapsed or refractory classical Hodgkin lymphoma: Pembrolizumab, as a monotherapy, shows overall response rates of 73 to 83%, with complete response rates of 27 to 30%
The findings from KEYNOTE-087, the phase 2 study investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, as...
Relapsing-remitting multiple sclerosis: Tysabri in highly active patients with inadequate response to prior therapy
The Committee of Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has...
Moderate to severe systemic lupus erythematosus: Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, improves symptoms in multiple organ domains including skin and joints
Anifrolumab is an investigational, fully human monoclonal antibody that binds to subunit 1 of the type I IFN receptor, inhibiting...